申请人:Sumitomo Pharma Co., Ltd.
公开号:US20220273649A1
公开(公告)日:2022-09-01
The present disclosure provides a compound that exerts an anticancer action based on CHK1 inhibition. The present disclosure was completed by finding that a compound represented by formula (1) or a pharmaceutically acceptable salt thereof exhibits an excellent antitumor action by having a potent inhibitory action against CHK1:
wherein R
1
, R
2
, L, V, W, and Q are as defined herein, X, Y, and Z each independently represent CR
8
or a nitrogen atom, wherein X, Y, and Z are not simultaneously CR
8
, and R
8
is as defined herein.
本公开提供了一种基于CHK1抑制的抗癌化合物。本公开通过发现由式(1)表示的化合物或其药学上可接受的盐具有对CHK1的强效抑制作用,从而表现出优异的抗肿瘤作用:其中R1、R2、L、V、W和Q如此定义,X、Y和Z各自独立地表示CR8或氮原子,其中X、Y和Z不同时为CR8,且R8如此定义。